Cairn Biosciences is developing the first technology platform for high throughput screening of disease biology in disease-relevant living cells. The firm's proprietary screening assays navigate the landscape of cellular targets and processes through real-time visualization of compound-drug target interactions and dynamic pathway and phenotypic changes. The firm's developed library of rapidly customizable multicolor cellular models enables turnkey implementation of robust multiparameter live cell assays. By measuring the dynamic behavior of cellular machinery, the firm's live cell high-content screening (LC-HCS) platform pinpoints and measures the diverse aspects of cellular physiology that are perturbed by candidate therapeutics, biological stimuli and disease pathologies. These capabilities are intended to accelerate the pace of early stage discovery of therapeutic compounds, reduce the rate of compound attrition in late stage drug discovery and enable improved predictive toxicology assays to evaluate new chemicals and biological agents for the risks they may pose to human health.
